Michel Vounatsos, Biogen CEO (Credit: World Economic Forum/Valeriano Di Domenico)

Bio­gen slash­es Aduhelm price in half, fore­shad­ows sig­nif­i­cant lay­offs as sales con­tin­ue to stag­nate

In a sur­prise move, Bio­gen an­nounced Mon­day that it will cut the price of its con­tro­ver­sial Alzheimer’s drug Aduhelm in half, slash­ing the cost from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA